45 results about "Macular oedema" patented technology

Diabetes is a disease characterized by high levels of blood glucose. It is important to keep diabetes under control to avoid short- and long-term complications. Diabetes can affect vision due to the alterations it produces in the blood vessels of the retina. This is known as Diabetic Retinopathy (DR), which is one of the leading causes of impaired vision in developed countries. One of the complications of diabetic retinopathy is Diabetic Macular Edema (DME), which is the leading cause of vision loss in diabetic patients and can appear at any stage of diabetic retinopathy. This consists of the gradual accumulation of fluid in the macula, the most important area of the retina. The determination of diabetic macular oedema is very important for the retina. The determination of diabetic macular oedema is very important for adequate treatment of this condition. A variety of technological options are used for detecting diabetic retinopathy, although only the most sophisticated detect macular oedema, a complication that appears as a consequence of diabetic retinopathy and is one of the leading causes of blindness. The invention describes a portable system for detecting diabetic macular oedema by capturing a fundus image using a portable ophthalmoscope; said image is sent via wired or wireless means to an embedded system that has an algorithm based on artificial intelligence, which extracts information from the image and processes same to identify the presence of the condition being studied.

The present disclosure relates to fusion molecules and chimeric molecules which comprise two components: an Ang-2 antagonist peptide linked to a VEGF-binding moiety. Further disclosed are methods of using said chimeric molecules to treat a patient cancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).

The present invention provides a compound of Formula Iand pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The embodiment of the invention provides a method for acquiring maculopathy edema features in a retina image and electronic equipment, and relates to the technical field of image recognition. The method for acquiring the maculopathy edema features in the retina images comprises the following steps: acquiring a current retina image to be recognized in a plurality of retina images; determining an edema brightness threshold value of the current retina image based on the brightness value of the pixel in the vitreous body region of the current retina image; based on the brightness value of each pixel in the current retina image and an edema brightness threshold value of the current retina image, an edema area in the current retina image is determined, and the brightness value of the pixel in the edema area is smaller than the edema brightness threshold value. According to the invention, feature extraction can be carried out on the macular oedema region in the image based on the brightness value of the pixel in the retina image.

The invention provides extracellular vesicle proteins sPTPRG and Vincin of a biomarker for detecting retinal vein obstructive macular edema (RVO-ME) anti-VEGF treatment typing, the difference of the expression quantity of the extracellular vesicle proteins in aqueous humor of a patient is analyzed, the protein with remarkable expression difference is screened out, the protein can be used as the biomarker for RVO-ME treatment, and the application of the biomarker for detecting the anti-VEGF treatment typing of the retinal vein obstructive macular edema (RVO-ME) anti-VEGF treatment typing of the RVO-ME anti-VEGF treatment typing is facilitated. Important guidance is provided for personalized treatment of RVO-ME, and the method has a wide clinical application prospect.

The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.

The invention is concerned with a method of predicting response to an IL-6 angatonist such as anti-IL-6 antibody by determing the concentration of IL-6 in human aqueous humor. The invention is also concerned with an IL-6 angatonist for use in treatment of uveitis or uveitic macular edema.

Pharmaceutical compositions comprising adeno-associated virus (AAV) and their use in treating diabetic macular edema are provided herein. In some aspects, treatment methods encompass co-administration of one or more corticosteroids and / or supplemental administrations of aflibercept protein.

The present invention relates to a method of predicting response to an IL-6 antagonist, such as an anti-IL-6 antibody, by determining the concentration of IL-6 in human aqueous humor. The invention also relates to an IL-6 antagonist for use in the treatment of uveitis or uveitis macular edema.

The present invention relates to a method for the production of an ocular implant, wherein dexamethasone — commonly employed in the treatment of macular edema resulting from retinal vein occlusion (RVO) and diabetic macular edema (DME) — is encapsulated within a nanofibrous matrix fabricated via electrospinning, and said nanofibers are subsequently coated onto a contact lens surface.

The invention provides a compound medicine for treating macular edema after cataract phacoemulsification and a preparation method of the compound medicine, and relates to the field of medicines. The compound medicine is prepared from the following raw materials in parts by weight: 18 to 23 parts of herba hedyotidis diffusae, 18 to 23 parts of rhizoma alismatis, 13 to 17 parts of herba artemisiae scopariae, 13 to 17 parts of rhizoma smilacis glabrae, 13 to 17 parts of semen plantaginis, 8 to 12 parts of rhizoma atractylodis, 8 to 12 parts of fructus gardeniae, 10 to 15 parts of white hyacinth bean, 10 to 15 parts of fructus rosae laevigatae, 8 to 12 parts of semen euryales The compound medicine disclosed by the invention is used for treating the macular edema after the cataract phacoemulsification, all the medicines are coordinated and synergistic, the effects of promoting urination and attacking evil, strengthening the spleen and consolidating the foundation, eliminating evil and calming the body resistance are achieved, microcirculation is improved, expression of peripheral blood VEGF (vascular endothelial growth factor) is reduced, vascular permeability is effectively promoted, retina recovery is promoted, and the like. The traditional Chinese medicine composition has a good clinical effect on treating macular edema after cataract ultrasonic emulsification, and has no side effect.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The present invention belongs to the field of tumor immunotherapy, and relates to a humanized anti-VEGF antibody Fab fragment. The present invention discloses nucleic acid sequences (including heavy / light chain variable regions) encoding said antibody fragment, and vectors, pharmaceutical compositions and kits containing said nucleic acid sequences. The anti-VEGF antibody Fab fragments disclosed in the present invention can specifically bind to VEGF with high affinity and block the binding of VEGF to the receptor VEGFR2, and also neutralize the proliferative effect of VEGF on HUVEC cells. Compared to the full-length antibody, antibodies in the form of Fab fragments have stronger penetrability and less toxic in terms of gastrointestinal perforation, hypertension and hemorrhage and do not stimulate the complement cascade reaction, thus reducing the risk of endophthalmitis and autoimmune inflammatory reactions. Thus it could be used in clinical treatment of ocular diseases characterized by choroidal neovascularization, including but not limited to age-related macular degeneration (AMD), diabetic macular edema (DME), retinal edema, degenerative myopia, choroidal neovascularization (CNV).

The invention relates to a traditional Chinese medicine composition for treating macular edema, which is prepared from the following traditional Chinese medicines in parts by weight: 5-35 parts of astragalus mongholicus, 1-30 parts of radix rehmanniae recen, 1-30 parts of radix angelicae, 1-30 parts of rhizoma atractylodis macrocephalae and 1-30 parts of rhizoma atractylodis macrocephalae. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 1-30 parts of poria cocos, 1-20 parts of radix achyranthis bidentatae, 1-20 parts of moutan bark, 1-20 parts of fructus gardeniae, 1-20 parts of radix salviae miltiorrhizae, 1-20 parts of radix scrophulariae, 1-20 parts of radix ophiopogonis, 1-20 parts of radix paeoniae alba, 1-15 parts of radix curcumae, 1-10 parts of radix notoginseng and 1-10 parts of lotus leaves. The traditional Chinese medicine composition can effectively relieve macular edema after macular anterior membrane vitrectomy, has positive effects on improving the inflammatory state, microcirculation and metabolic function of a macular region of a patient, and is safe in clinical use.

An ophthalmic preparation for treating macular edema, optic neuritis and non-infectious endophthalmitis contains an active ingredient for treating eye diseases and an ophthalmic preparation carrier or auxiliary material. The active ingredient for treating eye diseases is a glucocorticoid medicine and / or a non-steroidal medicine. The ophthalmic preparation carrier or auxiliary material contains the following ingredients: a surfactant, an ionic polymer and a solvent, or the ophthalmic preparation carrier or auxiliary material contains the following ingredients: povidone with low polymerization degree, povidone with moderate polymerization degree and a solvent. The ophthalmic preparation can carry (wrap) the glucocorticoid and / or the non-steroidal medicines to penetrate through the anterior segment of eyes and be conveyed to the posterior segment of eyes to treat the macular edema, the optic neuritis and the non-infectious endophthalmitis in an eye drop administration mode, and the ophthalmic preparation has extremely excellent clinical use value and positive social significance.

To provide treatment of AMD using an AAV2 variant with aflibercept.SOLUTION: The present disclosure provides pharmaceutical compositions and methods thereof for treatment of age-related macular degeneration (AMD) in a subject by administering intravitreally a pharmaceutical composition adapted for gene therapy, comprising a vector having a nucleic acid sequence that encodes aflibercept. The present disclosure relates to pharmaceutical compositions and methods for prevention or treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR) in patients with DME, retinal vein occlusion, and related eye diseases or conditions, in a primate or human subject by administering intravitreally or subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector or viral particles (e.g., rAAV) comprising a nucleic acid encoding aflibercept or a functional fragment or variant thereof.SELECTED DRAWING: None

The present invention relates to a composition comprising IL-36 and / or IL-18 for use in treating ocular disorders such as age-related macular degeneration (AMD), macular oedema, retinopathy, diabetic retinopathy, and glaucoma. The present invention also relates to a method of identifying patients likely to respond to an anti-VEGF agent.

The present invention relates to a method for predicting response to an IL-6 antagonist, such as an anti-IL-6 antibody, by determining the concentration of IL-6 in human aqueous humor. The present invention also relates to an IL-6 antagonist for use in treating uveitis or uveitic macular edema.

The present invention relates to novel methods, uses and compositions of annexin A5 protein as combination therapy with one or more anti-VEGF agents, the present invention relates to compounds, for example, for the prevention or treatment of macular edema, retinal vein occlusion and / or one or more diseases, conditions or conditions associated with and / or caused by macular edema or retinal vein occlusion, and / or other conditions suitable for treatment with anti-VEGF agents. In a preferred embodiment, the annexin A5 is administered systemically, such as intravenously.

Provided herein are methods of treating an eye disorder, including, for example, diabetic macular edema (DME) or macular edema secondary to inflammation (MESI) or wet age-related macular degeneration (wAMD), by administering a fusion protein and / or a conjugate thereof to a subject in need thereof.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The invention relates to novel methods, uses and compositions of a molecule consisting of monomeric Annexin A5 protein, for the prophylaxis or the treatment of macular oedema and / or one or more diseases, disorders or conditions associated with, and / or caused by, macular oedema. In a preferred embodiment, the Annexin A5 is administered systemically, such as intravenously.

Provided are methods of treating an ocular disease (e.g.,neovascular age-related macular degeneration, age-related macular degeneration, diabetic macular edema, choroidal neovascularization (including myopic choroidal neovascularization (mCNV), angioid streaks, choroiditis (including choroiditis secondary to ocular histoplasmosis), idiopathic degenerative myopia, retinal dystrophies, rubeosis iridis, pseudoxanthoma elasticum, and trauma), macular edema following retinal vein occlusion, central retinal vein occlusion, cystoid macular edema, glaucoma (e.g., neovascular glaucoma), polypoidal choroidal vasculopathy, retinopathy of prematurity, ocular von Hippel Lindau disease lesions, diabetic retinopathy, and retinitis pigmentosa) in a human patient by administering to the patient gedatolisib, or a pharmaceutically acceptable salt, solvate, or ester thereof, in an amount and with a frequency sufficient to treat the ocular disease.

The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating fibrosis, macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.

The present invention relates to novel methods, uses and compositions of molecules consisting of the monomeric annexin A5 protein for the prevention or treatment of macular edema and / or one or more diseases, conditions or conditions associated with and / or caused by macular edema. In a preferred embodiment, the annexin A5 is administered systemically, such as intravenously.

Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for treating ocular diseases or conditions, including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. The compositions and methods comprise steroids and prostaglandins that exhibit anti-inflammatory activity, reduce intraocular pressure (IOP), and / or other desirable activities. Injection of the compositions in the eye provides therapeutic benefits to patients suffering from ocular conditions.

The invention provides methods, compositions, and kits containing a first therapeutic agent that is a substituted 2,3-dimethoxyquinone of Formula I, or a pharmaceutically acceptable salt thereof, for preventing the progression of diabetic retinopathy, diabetic macular edema, and / or other retinal disorders and / or other disorders.